Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erming Tian

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Oncotarget|June 21, 2014
Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosisXenofon Papanikolaou, Sarah Johnson, Tarun Garg, et al.
British Journal of Haematology|December 11, 2019
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcomeMeera Mohan, Niels Weinhold, Carolina Schinke, et al.
Journal of Hematology & Oncology|September 2, 2016
Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitroThea Kristin Våtsveen, Anne-Marit Sponaas, Erming Tian, et al.
European Journal of Haematology|February 4, 2009
c-Met signaling promotes IL-6-induced myeloma cell proliferationHåkon Hov, Erming Tian, Toril Holien, et al.
Blood|November 11, 2011
An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplificationOwen W Stephens, Qing Zhang, Pingping Qu, et al.
British Journal of Haematology|December 21, 2002
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy IIJohn Shaughnessy, Erming Tian, Jeffrey Sawyer, et al.
Plos One|February 14, 2013
An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cellsMirta M L Sousa, Kamila Anna Zub, Per Arne Aas, et al.
British Journal of Haematology|September 12, 2009
Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 ampliconJeffrey R Sawyer, Erming Tian, Edward Thomas, et al.
Genes, Chromosomes & Cancer|July 30, 2015
Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpressionErming Tian, Magne Børset, Jeffrey R Sawyer, et al.
Gynecologic Oncology|May 17, 2005
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridizationAlessandro D Santin, Stefania Bellone, Sue Van Stedum, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Oncotarget|June 21, 2014
Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosisXenofon Papanikolaou, Sarah Johnson, Tarun Garg, et al.
British Journal of Haematology|December 11, 2019
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcomeMeera Mohan, Niels Weinhold, Carolina Schinke, et al.
Journal of Hematology & Oncology|September 2, 2016
Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitroThea Kristin Våtsveen, Anne-Marit Sponaas, Erming Tian, et al.
European Journal of Haematology|February 4, 2009
c-Met signaling promotes IL-6-induced myeloma cell proliferationHåkon Hov, Erming Tian, Toril Holien, et al.
Blood|November 11, 2011
An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplificationOwen W Stephens, Qing Zhang, Pingping Qu, et al.
British Journal of Haematology|December 21, 2002
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy IIJohn Shaughnessy, Erming Tian, Jeffrey Sawyer, et al.
Plos One|February 14, 2013
An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cellsMirta M L Sousa, Kamila Anna Zub, Per Arne Aas, et al.
British Journal of Haematology|September 12, 2009
Evidence for a novel mechanism for gene amplification in multiple myeloma: 1q12 pericentromeric heterochromatin mediates breakage-fusion-bridge cycles of a 1q12 approximately 23 ampliconJeffrey R Sawyer, Erming Tian, Edward Thomas, et al.
Genes, Chromosomes & Cancer|July 30, 2015
Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpressionErming Tian, Magne Børset, Jeffrey R Sawyer, et al.
Gynecologic Oncology|May 17, 2005
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridizationAlessandro D Santin, Stefania Bellone, Sue Van Stedum, et al.
Pageof 5